🔗 Permalink

Inventor profile of:

Daniel DIX

City:

Lagrangeville, New York

Country:

United States

Published Applications:

Last publication date:

2025-08-14

Top Assignees for applications by Daniel DIX

The entities that hold a legal rights for patent applications filed by inventor DIX Daniel:

Regeneron Pharmaceuticals, Inc. 30 Tarrytown, NY United States
Regeneron Pharmacuticals, Inc. 1 Tarrytown, NY United States

Recent patent applications by DIX Daniel

Daniel DIX from Lagrangeville, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-14

US20250257118A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#2 | 2025-02-06

US20250042972A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#3 | 2023-11-23

US20230374108A1

Chemistry; metallurgy

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

#4 | 2021-11-04

US20210340220A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#5 | 2020-04-30

US20200131246A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#6 | 2020-01-16

US20200017572A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#7 | 2019-08-01

US20190231877A1

Human necessities

Process for reducing subvisible particles in a pharmaceutical formulation

#8 | 2019-04-25

US20190117767A1

Human necessities

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

#9 | 2019-01-31

US20190031735A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#10 | 2018-06-07

US20180155408A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#11 | 2017-03-23

US20170080086A1

Human necessities

METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES

#12 | 2016-07-28

US20160213608A1

Human necessities

VEGF antagonist formulations suitable for intravitreal administration

#13 | 2016-06-23

US20160175439A1

Human necessities

Stable VEGF antagonist formulations

#14 | 2016-05-26

US20160144025A1

Human necessities

METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES

#15 | 2016-04-14

US20160101181A1

Human necessities

Process for reducing subvisible particles in a pharmaceutical formulation

#16 | 2015-03-19

US20150079087A1

Chemistry; metallurgy

Stable liquid formulations of dimer VEGF antagonists

#17 | 2014-10-30

US20140323983A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#18 | 2013-12-05

US20130323260A1

Human necessities

Stabilized formulations containing anti-DLL4 antibodies

#19 | 2013-10-17

US20130274189A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#20 | 2013-10-03

US20130261056A1

Human necessities

Stable liquid VEGF antagonist formulations

#21 | 2013-07-25

US20130189277A1

Human necessities

Stabilized formulations containing anti-PCSK9 antibodies

#22 | 2012-07-12

US20120178683A1

Human necessities

Stable liquid VEGF antagonist formulations

#23 | 2012-04-26

US20120101035A1

Human necessities

Dimer VEGF antagonist formulations

#24 | 2012-04-12

US20120087929A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#25 | 2012-01-19

US20120014968A1

Chemistry; metallurgy

STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES

#26 | 2011-10-20

US20110257601A1

Chemistry; metallurgy

VEGF antagonist formulations for intravitreal administration

#27 | 2010-11-04

US20100279933A1

Human necessities

VEGF antagonist formulations

#28 | 2010-03-25

US20100075903A1

Chemistry; metallurgy

Lyophilized VEGF antagonist formulations for intravitreal administration

#29 | 2008-01-17

US20080015148A1

Human necessities

IL-1 antagonist formulations

#30 | 2007-12-20

US20070293432A1

Chemistry; metallurgy

VEGF antagonist formulations suitable for intravitreal administration

#31 | 2006-09-28

US20060217311A1

Human necessities

VEGF antagonist formulations

#32 | 2006-02-23

US20060040852A1

Human necessities

IL-1 antagonist formulations

InventorID:

353733 ⎘